Department of Physiology, Faculty of Medicine, Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia.
Department of Physiology, Faculty of Medicine, Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia.
Pharmacol Ther. 2021 Aug;224:107832. doi: 10.1016/j.pharmthera.2021.107832. Epub 2021 Mar 1.
Diabetes mellitus is associated with endothelial dysfunction that leads to cardiovascular complications. Sodium-glucose cotransporter 2 (SGLT2) inhibitors demonstrated efficacy in glycemic control in type 2 diabetes patients with positive cardiovascular outcome. Recent research revealed a link between SGLT2 inhibition and improved macro- and microvascular endothelial functions. Mechanisms underlying this phenomenon could be due to the role of SLGT2 in the regulation of endothelial physiology. In this review, current knowledge and hypothesis on the link between SGLT2 and endothelial function were critically appraised and the impact of SGLT2 inhibitors on endothelial dysfunction in pre-clinical and clinical studies was discussed.
糖尿病与内皮功能障碍有关,后者可导致心血管并发症。钠-葡萄糖共转运蛋白 2(SGLT2)抑制剂在 2 型糖尿病患者的血糖控制中显示出疗效,并具有心血管结局获益。最近的研究揭示了 SGLT2 抑制与改善大血管和微血管内皮功能之间的联系。这种现象的机制可能归因于 SGLT2 在调节内皮生理中的作用。在这篇综述中,我们批判性地评估了 SGLT2 与内皮功能之间的联系的现有知识和假设,并讨论了 SGLT2 抑制剂在临床前和临床研究中对内皮功能障碍的影响。